



Atty. Dkt. No.: 124263-1006

Patent

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/713,578
First Named Inventor : Sanjay Awasthi
Filing Date : November 13, 2003
Title : LIPOSOMES FOR PROTECTION AGAINST TOXIC ORGANIC COMPOUNDS
Group Art Unit : 1642
Examiner : B. Fetterolf

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope, with sufficient postage, addressed to: Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 this 6 day of December, 2005

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Stella E. Laicer
Signature
Stella E. Laicer
Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the provisions of 37 C.F.R. § 1.97, submitted herewith are copies of the literature references listed on the accompanying form PTO/SB/08A. A copy is not provided of the U.S. Patent reference listed on the attached form PTO/SB/08A. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists.

Written notification that the enclosed references have been considered in their entirety by return of a copy of the enclosed form, completed by the Examiner, is respectfully requested.

This Information Disclosure Statement is being filed before the mailing date of the First Office Action on the merits. Accordingly, Applicants believe no fees are due for the filing of this IDS. However, if any additional fees are due, or any overpayments have been made, please charge, or credit, Deposit Account No. 07-0153.

Respectfully submitted,

Date: Dec. 6, 2005

Monique A. Vander Molen
Monique A. Vander Molen
Registration No. 53,716

Gardere Wynne Sewell LLP
1601 Elm Street, Suite 3000
Dallas, Texas 75201-4761
214-999-3000

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> Sheet <u>2</u> of <u>2</u>	Complete If Known	
	Application Number	10/714,578
	Filing Date	November 13, 2003
	First Named Inventor	Sanjay Awasthi
	Art Unit	1642
	Examiner Name	B. Fetterolf
	Attorney Docket Number	124263-1006

NON PATENT LITERATURE DOCUMENTS			T ²
Examiner Initial*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
		William T. Sause, Chest, 116(6):504S-508S (12/1999 Supplement)	
		Sharad S. Singhal et al, ACTA Biochimica Polonica, Vol. 48(2), pp. 551-562 (2001)	
		American Type Culture Collection (Tumor Cell Lines, 2001)	
		Sushma Yadav et al, Biochemistry 43:16243-16253 (2004)	
		Sanjay Awasthi et al, BMC Neuroscience 6:61-71 (2005)	
		Sharad Singhal et al, FEBS Letters 579:4635-4641 (2005)	
		Abstract: Sanjay Awasthi et al, A Novel Mechanism of Drug Resistance in Epilepsy, Blood Brain Barrier Conference at Cleveland Clinic Foundation, Cleveland, OH, November 2-3, 2004	
		Abstract: Sanjay Awasthi et al, Targeting Multiple Signaling Pathways with RLIP76, Gordon Conference on Molecular Therapeutics of Cancer, Colby Sawyer College, New London New Hampshire, July 20, 2005	
Examiner Signature			Date Considered

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional.). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2